Ablynx NV [ABLX] is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, haematology, oncology and pulmonary disease. The unique characteristics of Nanobodies and continuous innovation have allowed Ablynx, and its partners, to develop differentiated drug products such as both antagonistic and agonistic Nanobodies, bispecific Nanobodies, Nanobodies against challenging targets such as ion channels and GPCRs, Nanobodies that are administered through alternative routes of administration and Nanobodies half-lives which can be modulated from hours to days to weeks.